Is Travere Therapeutics (TVTX) Facing a Credibility Test in Its Disclosure and Risk Narrative? [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
Therapeutics, Inc., focusing on whether the company and certain executives made false or misleading statements or omitted key information about its business and operations. The move signals rising legal and regulatory scrutiny around Travere's disclosures, prompting investors and other stakeholders to reassess the company's transparency and risk profile. Next, we examine how this securities law investigation and the questions it raises about disclosure practices shape Travere's broader investment narrative. These 15 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs . Discover why before your portfolio feels the trade war pinch. To own Travere Therapeutics today, you really need to believe that FILSPARI can translate its clinical and regulatory momentum in IgAN and potential FSGS approval into a durable rare-kidney-disease franchise, while the company moves from losses toward sustained profitability. The key short term catalyst
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Travere Therapeutics (NASDAQ:TVTX) had its "neutral" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech SummitBusiness Wire
- TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law FirmGlobeNewswire
- Travere Therapeutics: Filspari's FSGS Approval Chance Is Higher Than You Think [Seeking Alpha]Seeking Alpha
TVTX
Earnings
- 10/30/25 - Beat
TVTX
Sec Filings
- 2/9/26 - Form SCHEDULE
- 2/5/26 - Form 4
- 2/5/26 - Form 4
- TVTX's page on the SEC website